Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system

BACKGROUND: For many cancer types, including colorectal carcinoma (CRC), combined modality treatments have shown to improve outcome, but are frequently associated with significant toxicity, illustrating the need for new therapeutic approaches. Based on preclinical data, TRAIL receptor agonists appea...

Descripción completa

Detalles Bibliográficos
Autores principales: Zerp, Shuraila F., Bibi, Zainab, Verbrugge, Inge, Voest, Emile E., Verheij, Marcel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303921/
https://www.ncbi.nlm.nih.gov/pubmed/32577539
http://dx.doi.org/10.1016/j.ctro.2020.05.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303921/
https://www.ncbi.nlm.nih.gov/pubmed/32577539
http://dx.doi.org/10.1016/j.ctro.2020.05.012

Ejemplares similares